Literature DB >> 27925820

A Major Shortcoming in the Public Health Legacy of the Obama Administration.

Diana M Zuckerman1.   

Abstract

Mesh：

Year:  2017        PMID： 27925820      PMCID： PMC5308193          DOI： 10.2105/AJPH.2016.303559

Source DB:  PubMed          Journal:  Am J Public Health        ISSN： 0090-0036            Impact factor:   9.308


× No keyword cloud information.
  5 in total

1.  Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.

Authors:  Chul Kim; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2015-12       Impact factor: 21.873

2.  The FDA as a public health agency.

Authors:  Margaret A Hamburg; Joshua M Sharfstein
Journal:  N Engl J Med       Date:  2009-05-26       Impact factor: 91.245

3.  Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

4.  Lack of publicly available scientific evidence on the safety and effectiveness of implanted medical devices.

Authors:  Diana Zuckerman; Paul Brown; Aditi Das
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

5.  Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.

Authors:  Vinay K Rathi; Harlan M Krumholz; Frederick A Masoudi; Joseph S Ross
Journal:  JAMA       Date:  2015-08-11       Impact factor: 56.272
  5 in total
  1 in total

1.  Can the FDA Help Reduce Drug Prices or the Cost of Medical Care?

Authors:  Diana M Zuckerman
Journal:  Am J Public Health       Date:  2017-11       Impact factor: 9.308
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.